Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2022-04-15 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司高级管理人员暨核心技术人员离职的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed verification opinion from the underwriting and sponsorship institution (方正证券承销保荐有限责任公司) regarding the departure of a senior management and core technical personnel (JIN XIA) from Shanghai Sailun Biotechnology Co., Ltd. It includes background information on the individual, impact assessment on the company, confidentiality and non-compete agreements, and the sponsor's conclusion that the departure will not adversely affect the company. The document is not a financial report, earnings release, or regulatory filing about financial results. It is not an announcement of voting results, capital changes, or legal proceedings. It is a specialized report related to management personnel changes but focuses on the verification and impact assessment of a senior management and core technical personnel departure. This fits best under Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document length is under 5,000 characters, but it is a substantive report, not a mere announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2022-04-15 Chinese
赛伦生物：关于高级管理人员暨核心技术人员离职的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding the resignation of a senior management and core technical personnel, Mr. Jin Xia. It details his departure, the impact on the company, confidentiality and non-compete agreements, and the company's measures to ensure smooth transition. There is no financial data, no mention of financial results, no regulatory filings about financial performance, no voting results, no capital changes, no legal proceedings, and no merger or acquisition activity. The document focuses solely on management changes, specifically the departure of a senior executive and core technical staff. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 2708 characters, which is relatively short but contains substantive information about management changes, not just a brief announcement or a report publication notice. Hence, the classification is MANG with high confidence.
2022-04-15 Chinese
赛伦生物：独立董事关于第三届董事会第六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting resolution about the use of temporarily idle raised funds for cash management. It references compliance with company law, listing rules, and regulatory guidelines. The content is focused on governance and regulatory compliance related to board decisions, not a full financial report or earnings release. The document length is short (710 characters) and it is a formal opinion on a board matter, not a report or announcement of voting results. This fits best under Board/Management Information (MANG), which covers announcements of board decisions and related management information.
2022-03-21 Chinese
赛伦生物：第三届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board (监事会) of Shanghai SAILUN Biotechnology Co., Ltd. It details the convening and resolution of the Supervisory Board's fourth meeting of the third session, including approval of a proposal to use temporarily idle raised funds for cash management. The document includes voting results and compliance statements with relevant laws and regulations. It is not a full financial report, audit report, or earnings release, but rather a formal meeting resolution announcement. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about internal supervisory board decisions and fund usage, not a full report or presentation.
2022-03-21 Chinese
赛伦生物：方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司使用暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from the underwriting and sponsoring institution regarding the company's use of temporarily idle raised funds for cash management. It references regulatory rules, approval from the board, and compliance with listing rules. The document does not contain financial statements or quarterly/yearly financial results but focuses on the compliance and procedural aspects of the cash management of raised funds. It is not an announcement of a report but a verification opinion related to regulatory compliance and fund usage. This fits best under the category of Regulatory Filings (RNS), as it is a compliance-related disclosure that does not fit into other specific report categories like Annual Report, Interim Report, or Capital/Financing Update.
2022-03-21 Chinese
赛伦生物：关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai SAILUN Biotech Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee approvals, the amount and purpose of the cash management, risk controls, and compliance with regulatory requirements. The document references regulatory guidelines and approvals related to the use of raised funds but does not contain financial statements or detailed financial performance data. It is a formal disclosure about the company's capital management activities related to fundraising proceeds, not a full financial report or earnings release. The document length is 4233 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits best under the category of Capital/Financing Update (CAP), as it updates on the company's use of fundraising proceeds and capital management activities.
2022-03-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.